<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36647114</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART).</ArticleTitle><Pagination><StartPage>29</StartPage><MedlinePgn>29</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">29</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-07007-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with motor neuron disease. Initially, the treatments memantine and trazodone will each be compared against placebo, but other investigational treatments will be introduced into the trial later. The co-primary outcomes are the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R) functional outcome, which is assessed longitudinally, and overall survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Initially in MND-SMART, participants are randomised 1:1:1 via a minimisation algorithm to receive placebo or one of the two investigational treatments with up to 531 to be randomised in total. The comparisons between each research arm and placebo will be conducted in four stages, with the opportunity to cease further randomisations to poorly performing research arms at the end of stages 1 or 2. The final ALS-FRS-R analysis will be at the end of stage 3 and final survival analysis at the end of stage 4. The estimands for the co-primary outcomes are described in detail. The primary analysis of ALS-FRS-R at the end of stages 1 to 3 will involve fitting a normal linear mixed model to the data to calculate a mean difference in rate of ALS-FRS-R change between each research treatment and placebo. The pairwise type 1 error rate will be controlled, because each treatment comparison will generate its own distinct and separate interpretation. This publication is based on a formal statistical analysis plan document that was finalised and signed on 18 May 2022.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In developing the statistical analysis plan, we had to carefully consider several issues such as multiple testing, estimand specification, interim analyses, and statistical analysis of the repeated measurements of ALS-FRS-R. This analysis plan attempts to balance multiple factors, including minimisation of bias, maximising power and precision, and deriving clinically interpretable summaries of treatment effects.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EudraCT Number, 2019-000099-41. Registered 2 October 2019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=mnd-smart ClinicalTrials.gov, NCT04302870 . Registered 10 March 2020.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-2658-5022</Identifier><AffiliationInfo><Affiliation>Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK. Richard.Parker@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weir</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Tra My</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stallard</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Statistics and Epidemiology, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmar</LastName><ForeName>Mahesh K B</ForeName><Initials>MKB</Initials><AffiliationInfo><Affiliation>Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swingler</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Euan Macdonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Rachel S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Euan Macdonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan Macdonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan Macdonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04302870</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>DOD/14/15</GrantID><Agency>My Name'5 Doddie Foundation</Agency><Country/></Grant><Grant><GrantID>MC_UU_00004/07</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035703" MajorTopicYN="N">Therapies, Investigational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MAMS trial</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Multi-arm</Keyword><Keyword MajorTopicYN="N">Platform trial</Keyword><Keyword MajorTopicYN="N">Statistical analysis plan</Keyword></KeywordList><CoiStatement>CJW is a member of the independent data monitoring committee for a trial of masitinib in ALS, for which his institution receives funding from AB Science. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>16</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36647114</ArticleId><ArticleId IdType="pmc">PMC9843918</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-07007-z</ArticleId><ArticleId IdType="pii">10.1186/s13063-022-07007-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MND Association Website: What is MND? https://www.mndassociation.org/about-mnd/what-is-mnd/ Accessed 23rd March 2022.</Citation></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012(3):Art. No.:CD001447. 10.1002/14651858.CD001447.pub3. Accessed 12 Jan 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. 2008;100(17):1204&#x2013;1214. doi: 10.1093/jnci/djn267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djn267</ArticleId><ArticleId IdType="pmc">PMC2528020</ArticleId><ArticleId IdType="pubmed">18728279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Stat Methods Med Res. 2016;25(2):716&#x2013;727. doi: 10.1177/0962280212465498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280212465498</ArticleId><ArticleId IdType="pmc">PMC4843088</ArticleId><ArticleId IdType="pubmed">23242385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Dakin RS, Williamson J, Newton J, Steven M, Colville S, et al. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12:e064173. doi: 10.1136/bmjopen-2022-064173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-064173</ArticleId><ArticleId IdType="pmc">PMC9263927</ArticleId><ArticleId IdType="pubmed">35798516</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;1725. doi: 10.1212/WNL.0000000000000951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>PRO-ACT Open Access ALS Clinical Trial database. http://www.alsdatabase.org/ Accessed 7th April 2022.</Citation></Reference><Reference><Citation>Odutayo A, Gryaznov D, Copsey B, Monk P, Speich B, Roberts C, et al. Design, analysis and reporting of multi-arm trials and strategies to address multiple testing. Int J Epidemiol. 2020;49(3):968&#x2013;978. doi: 10.1093/ije/dyaa026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa026</ArticleId><ArticleId IdType="pubmed">32176282</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker RA, Weir CJ. Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification. Clin Trials. 2020;17(5):562&#x2013;6.&#xa0;10.1177/1740774520941419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534018</ArticleId><ArticleId IdType="pubmed">32666813</ArticleId></ArticleIdList></Reference><Reference><Citation>Collignon O, Gartner C, Haidich AB, Hemmings R, Hofner B, P&#xe9;tavy F, et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials. Clin Pharmacol Ther. 2020;107(5):1059&#x2013;1067. doi: 10.1002/cpt.1804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1804</ArticleId><ArticleId IdType="pubmed">32017052</ArticleId></ArticleIdList></Reference><Reference><Citation>Choodari-Oskooei B, Bratton DJ, Gannon MR, Meade AM, Sydes MR, Parmar MK. Adding new experimental arms to randomised clinical trials: impact on error rates. Clin Trials. 2020;17(3):273&#x2013;284. doi: 10.1177/1740774520904346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774520904346</ArticleId><ArticleId IdType="pmc">PMC7263043</ArticleId><ArticleId IdType="pubmed">32063029</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy SF, White IR, Nunn AJ, Hayes R, Wang D, Harrison TS. Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: clear guidance is needed. Contemp Clin Trials. 2022;1(113):106656. doi: 10.1016/j.cct.2021.106656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2021.106656</ArticleId><ArticleId IdType="pmc">PMC8844584</ArticleId><ArticleId IdType="pubmed">34906747</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708&#x2013;15. 10.1016/j.jval.2012.02.008. Epub 2012 May 24. PMID: 22867780.</Citation><ArticleIdList><ArticleId IdType="pubmed">22867780</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol website: Crosswalk Index Value Calculator https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/ Accessed 23/03/2022.</Citation></Reference><Reference><Citation>Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7&#x2013;22. doi: 10.1002/hec.3564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3564</ArticleId><ArticleId IdType="pmc">PMC6680214</ArticleId><ArticleId IdType="pubmed">28833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hout B, Mulhern B, Feng Y, Shah K, Devlin N. The EQ-5D-5L value set for England: response to the &#x201c;Quality Assurance&#x201d;. Value in Health. 2020;23(5):649&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32389231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurland BF, Johnson LL, Egleston BL, Diehr PH. Longitudinal data with follow-up truncated by death: match the analysis method to research aims. Stat Sci. 2009;24(2):211. doi: 10.1214/09-STS293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/09-STS293</ArticleId><ArticleId IdType="pmc">PMC2812934</ArticleId><ArticleId IdType="pubmed">20119502</ArticleId></ArticleIdList></Reference><Reference><Citation>Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data.&#xa0;Oxford: Oxford University Press;&#xa0;1994.</Citation></Reference><Reference><Citation>Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13&#x2013;22. doi: 10.1093/biomet/73.1.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/73.1.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter JR, Kenward MG. Missing data in randomised controlled trials: a practical guide. Health Technology Assessment Methodology Programme, Birmingham, p. 199. https://researchonline.lshtm.ac.uk/id/eprint/4018500</Citation></Reference><Reference><Citation>ICH Website: E9 (R1) EWG Addendum: statistical principles for clinical trials, https://www.ich.org/page/efficacy-guidelines#9-2 Accessed 23/03/2022.</Citation></Reference><Reference><Citation>Gorrie GH, Chandran S, Colville S, Newton J, Leighton D, McDonald M, et al. Improved survival and 30-day mortality after gastrostomy in Scottish motor neurone disease patients: evidence from a national retrospective cohort study using STROBE criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):165&#x2013;171. doi: 10.1080/21678421.2019.1570271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1570271</ArticleId><ArticleId IdType="pubmed">30835562</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Hopewell S, Schulz KF, Montori V, G&#xf8;tzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28&#x2013;55. doi: 10.1016/j.ijsu.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2011.10.001</ArticleId><ArticleId IdType="pubmed">22036893</ArticleId></ArticleIdList></Reference><Reference><Citation>CONSORT statement website. http://www.consort-statement.org Accessed 23/03/2022.</Citation></Reference><Reference><Citation>EudDRA CT website. https://eudract.ema.europa.eu/ Accessed 23/03/2022.</Citation></Reference><Reference><Citation>Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219&#x2013;242. doi: 10.1177/0962280206074463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280206074463</ArticleId><ArticleId IdType="pubmed">17621469</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. Multiple imputation for nonresponse in surveys. Wiley Series in Probability and Mathematical Statistics. New York: John Wiley &amp; Sons; 1987.</Citation></Reference><Reference><Citation>Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: a practical guide. Stat Med. 2020;39(21):2815&#x2013;2842. doi: 10.1002/sim.8569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8569</ArticleId><ArticleId IdType="pubmed">32419182</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40. doi: 10.1136/bmj.d40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d40</ArticleId><ArticleId IdType="pmc">PMC3230114</ArticleId><ArticleId IdType="pubmed">21300711</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X, Lee S, Li N. Missing data handling methods in medical device clinical trials. J Biopharm Stat. 2009;19(6):1085&#x2013;1098. doi: 10.1080/10543400903243009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10543400903243009</ArticleId><ArticleId IdType="pubmed">20183466</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PK, Geskus RB, de Witte T, et al. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861&#x2013;870. doi: 10.1093/ije/dyr213[publishedOnlineFirst:2012/01/19].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyr213[publishedOnlineFirst:2012/01/19]</ArticleId><ArticleId IdType="pmc">PMC3396320</ArticleId><ArticleId IdType="pubmed">22253319</ArticleId></ArticleIdList></Reference><Reference><Citation>Noordzij M, Leffondre K, van Stralen KJ, et al. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013;28(11):2670&#x2013;2677. doi: 10.1093/ndt/gft355[publishedOnlineFirst:2013/08/27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gft355[publishedOnlineFirst:2013/08/27</ArticleId><ArticleId IdType="pubmed">23975843</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadhan R, Weiss CO, Segal JB, et al. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care. 2010;48(6 Suppl):S96&#x2013;105. doi: 10.1097/MLR.0b013e3181d99107[publishedOnlineFirst:2010/05/18].</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3181d99107[publishedOnlineFirst:2010/05/18]</ArticleId><ArticleId IdType="pubmed">20473207</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker RA, Weir CJ. Multiple secondary outcome analyses: precise interpretation is important. Trials. 2022;23(1):1&#x2013;4.&#xa0;10.1186/s13063-021-05975-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8744058</ArticleId><ArticleId IdType="pubmed">35012627</ArticleId></ArticleIdList></Reference><Reference><Citation>MedDRA website. https://www.meddra.org/. Accessed 23/03/2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>